11-valent recombinant human papilloma virus vaccine (Hansenula polymorpha)

BIOLOGICAL2 trials

Sponsors

National Vaccine and Serum Institute, China

Conditions

HPV InfectioNHPV InfectionHPV-Related CarcinomaHPV-Related Cervical Carcinoma

Phase 1

A Randomized, Blinded, Placebo-controlled Phase I Clinical Trial Evaluating the Safety and Preliminary Immunogenicity of a 11-valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) in Chinese Women Aged 9-45 Years

CompletedNCT04083196

National Vaccine and Serum Institute, ChinaHPV Infection, HPV-Related Cervical Carcinoma

Start: 2019-09-07End: 2021-10-13Updated: 2021-11-24

Phase 3

A Phase III Clinical Trial of a 11-valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) in Chinese Women Aged 9-45 Years

RecruitingNCT05262010

National Vaccine and Serum Institute, ChinaHPV InfectioN, HPV-Related Carcinoma

Start: 2022-06-04End: 2028-06-01Target: 13500Updated: 2026-01-16